Bruce Wendel

Filings by Bruce Wendel span 2 companies, the busiest being New Abraxis, Inc. and GT Biopharma, Inc. Over a trading history stretching from 5 November 2008 to 16 February 2021, the count stands at 15 filings.

On the open market, the record shows 3 purchases worth €22k and 1 sale worth €19k. Netting one side against the other leaves €2,936 of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 9 share grants and 1 option exercise. 2021 to date brings 3 purchases and no sales.

Half of the purchases are above €8,663 and half below. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -49.7%. Past outcomes like these are no guarantee of what comes next.

On 7 October 2021 came the latest disclosure, an open-market purchase for €9,960 in GT Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.